The promise and challenge of epitope-focused vaccines

Oscherwitz, Jon

doi:10.1080/21645515.2016.1160977

Cited by 53 publications

(42 citation statements)

References 34 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the potency of glycoprotein G over F, we have considered this incident to be the target of this study. There are a lot of challenges regarding the development of peptide-based vaccines, and therefore, we have decided to study and propose a new vaccine against the Nipah virus, since they make a helpful alternative strategy that relies on the usage of short peptide fragments to induce immune responses [23][24][25][26]. Antigenic epitopes from single proteins may not be really necessary, whereas some of these epitopes may even be detrimental to the induction of protective immunity.…”

Section: Introductionmentioning

confidence: 99%

Epitope-Based Peptide Vaccine against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches

Mohammed

Shantier

Mustafa

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Background. Nipah belongs to the genus Henipavirus and the Paramyxoviridae family. It is an endemic most commonly found at South Asia and has first emerged in Malaysia in 1998. Bats are found to be the main reservoir for this virus, causing disease in both humans and animals. The last outbreak has occurred in May 2018 in Kerala. It is characterized by high pathogenicity and fatality rates which varies from 40% to 70% depending on the severity of the disease and on the availability of adequate healthcare facilities. Currently, there are no antiviral drugs available for NiV disease and the treatment is just supportive. Clinical presentations for this virus range from asymptomatic infection to fatal encephalitis. Objective. This study is aimed at predicting an effective epitope-based vaccine against glycoprotein G of Nipah henipavirus, using immunoinformatics approaches. Methods and Materials. Glycoprotein G of the Nipah virus sequence was retrieved from NCBI. Different prediction tools were used to analyze the epitopes, namely, BepiPred-2.0: Sequential B Cell Epitope Predictor for B cell and T cell MHC classes II and I. Then, the proposed peptides were docked using Autodock 4.0 software program. Results and Conclusions. The two peptides TVYHCSAVY and FLIDRINWI have showed a very strong binding affinity to MHC class I and MHC class II alleles. Furthermore, considering the conservancy, the affinity, and the population coverage, the peptide FLIDRINWIT is highly suitable to be utilized to formulate a new vaccine against glycoprotein G of Nipah henipavirus. An in vivo study for the proposed peptides is also highly recommended.

show abstract

Section: Introductionmentioning

confidence: 99%

Epitope-Based Peptide Vaccine against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches

Mohammed

Shantier

Mustafa

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…The procedure, includes antigen selection, epitope prediction, vaccine engineering and vaccine evaluation. The results from the common protocol may be limited by some drawbacks such as inappropriate physicochemical properties of predicted epitopes or final construct, toxic epitopes, instability of final vaccine and unable to effective expression of designed vaccine in a desired host [43,44]. Therefore, in the present study, we used a special multi-steps procedure to decrease mentioned obstacles.…”

Section: Introductionmentioning

confidence: 99%

Towards the first multi-epitope recombinant vaccine against Crimean-Congo hemorrhagic fever virus: A computer-aided vaccine design approach

Nosrati

Behbahani

Mohabatkar

2019

Journal of Biomedical Informatics

View full text Add to dashboard Cite

A R T I C L E I N F O Keywords:Crimean-Congo hemorrhagic fever Computer-aided vaccine design Multi-epitope vaccine A B S T R A C T Crimean-Congo hemorrhagic fever (CCHF) is considered one of the major public health concerns with case fatality rates of up to 80%. Currently, there is no effective approved vaccine for CCHF. In this study, we used a computer-aided vaccine design approach to develop the first multi-epitope recombinant vaccine for CCHF. For this purpose, linear B-cell and T-cell binding epitopes from two structural glycoproteins of CCHF virus including Gc and Gn were predicted. The epitopes were further studied regarding their antigenicity, allergenicity, hydrophobicity, stability, toxicity and population coverage. A total number of seven epitopes including five T-cell and two B-cell epitopes were screened for the final vaccine construct. Final vaccine construct composed of 382 amino acid residues which were organized in four domains including linear B-cell, T-cell epitopes and cholera toxin B-subunit (CTxB) along with heat labile enterotoxin IIc B subunit (LT-IIc) as adjuvants. All the segments were joined using appropriate linkers. The physicochemical properties as well as the presence of IFN-γ inducing epitopes in the proposed vaccine, was also checked to determining the vaccine stability, solubility and its ability to induce cell-mediated immune responses. The 3D structure of proposed vaccine was subjected to the prediction of computational B-cell epitopes and molecular docking studies with MHC-I and II molecules. Furthermore, molecular dynamics stimulations were performed to study the vaccine-MHCs complexes stability during stimulation time. The results suggest that our proposed vaccine was stable, well soluble in water and potentially antigenic. Results also demonstrated that the vaccine can induce both humoral and cell-mediated immune responses and could serve as a promising anti-CCHF vaccine candidate.

show abstract

“…It could be the first vaccine developed for humans against glycoprotein G of Nipah henipavirus to be put forward using an immunoinformatics approach and population coverage analytical tools. Even though there's a lot of challenges regarding the development of peptide vaccines, we have decided to develop them for fighting the Nipah virus infection because they make a very good alternative strategy that relies on the usage of short peptide fragments to induce immune responses that are extremely targeted, avoiding all allergenic as well as reactogenic sequences [23][24][25][26] . Antigenic epitopes from single proteins may not be really necessary, whereas some of these epitopes may even be detrimental to the induction of protective immunity.…”

Section: Introductionmentioning

confidence: 99%

Epitope - based peptide vaccine against glycoprotein G of Nipah henipavirus using immunoinformatics approaches

Mohammed

Shantier

Mustafa

et al. 2019

Preprint

View full text Add to dashboard Cite

AbstractBackgroundNipah virus (NiV) is a member of the genus Henipavirus of the family Paramyxoviridae, characterized by high pathogenicity and endemic in South Asia, first emerged in Malaysia in 1998. The case-fatality varies from 40% to 70% depending on the severity of the disease and on the availability of adequate healthcare facilities. At present no antiviral drugs are available for NiV disease and the treatment is just supportive. Clinical presentation ranges from asymptomatic infection to fatal encephalitis. Bats are the main reservoir for this virus, which can cause disease in humans and animals. The last investigated NiV outbreak has occurred in May 2018 in Kerala.ObjectiveThis study aims to predict effective epitope-based vaccine against glycoprotein G of Nipah henipavirus using immunoinformatics approaches.Methods and MaterialsGlycoprotein G of Nipah henipavirus sequence was retrieved from NCBI. Different prediction tools were used to analyze the nominee’s epitopes in BepiPred-2.0: Sequential B-Cell Epitope Predictor for B-cell, T-cell MHC class II & I. Then the proposed peptides were docked using Autodock 4.0 software program.Results and ConclusionsPeptide TVYHCSAVY shows a very strong binding affinity to MHC I alleles while FLIDRINWI shows a very strong binding affinity to MHC II and MHC I alleles. This indicates a strong potential to formulate a new vaccine, especially with the peptide FLIDRINWI that is likely to be the first proposed epitope-based vaccine against glycoprotein G of Nipah henipavirus. This study recommends an in-vivo assessment for the most promising peptides especially FLIDRINWI.

show abstract

The promise and challenge of epitope-focused vaccines

Cited by 53 publications

References 34 publications

Epitope-Based Peptide Vaccine against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches

Epitope-Based Peptide Vaccine against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches

Towards the first multi-epitope recombinant vaccine against Crimean-Congo hemorrhagic fever virus: A computer-aided vaccine design approach

Epitope - based peptide vaccine against glycoprotein G of Nipah henipavirus using immunoinformatics approaches

Contact Info

Product

Resources

About